268 related articles for article (PubMed ID: 22932264)
1. Comparison of 2 contouring methods of bone marrow on CT and correlation with hematological toxicities in non-bone marrow-sparing pelvic intensity-modulated radiotherapy with concurrent cisplatin for cervical cancer.
Mahantshetty U; Krishnatry R; Chaudhari S; Kanaujia A; Engineer R; Chopra S; Shrivastava S
Int J Gynecol Cancer; 2012 Oct; 22(8):1427-34. PubMed ID: 22932264
[TBL] [Abstract][Full Text] [Related]
2. Acute hematological toxicity during post-operative bowel sparing image-guided intensity modulated radiation with concurrent cisplatin.
Lewis S; Chopra S; Naga P; Pant S; Dandpani E; Bharadwaj N; Mahantshetty U; Engineer R; Swamidas J; Ghosh J; Gupta S; Shrivastava S
Br J Radiol; 2018 Dec; 91(1092):20180005. PubMed ID: 30179056
[TBL] [Abstract][Full Text] [Related]
3. Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy.
Mell LK; Kochanski JD; Roeske JC; Haslam JJ; Mehta N; Yamada SD; Hurteau JA; Collins YC; Lengyel E; Mundt AJ
Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1356-65. PubMed ID: 16757127
[TBL] [Abstract][Full Text] [Related]
4. Can dosimetric parameters predict acute hematologic toxicity in rectal cancer patients treated with intensity-modulated pelvic radiotherapy?
Wan J; Liu K; Li K; Li G; Zhang Z
Radiat Oncol; 2015 Aug; 10():162. PubMed ID: 26238572
[TBL] [Abstract][Full Text] [Related]
5. Association between bone marrow dosimetric parameters and acute hematologic toxicity in cervical cancer patients undergoing concurrent chemoradiotherapy: comparison of three-dimensional conformal radiotherapy and intensity-modulated radiation therapy.
Hui B; Zhang Y; Shi F; Wang J; Wang T; Wang J; Yuan W; Li Y; Liu Z
Int J Gynecol Cancer; 2014 Nov; 24(9):1648-52. PubMed ID: 25275663
[TBL] [Abstract][Full Text] [Related]
6. Correlations Between Radiation Dose in Bone Marrow and Hematological Toxicity in Patients With Cervical Cancer: A Comparison of 3DCRT, IMRT, and RapidARC.
Chang Y; Yang ZY; Li GL; Li Q; Yang Q; Fan JQ; Zhao YC; Song YQ; Wu G
Int J Gynecol Cancer; 2016 May; 26(4):770-6. PubMed ID: 26844613
[TBL] [Abstract][Full Text] [Related]
7. Prospective study of functional bone marrow-sparing intensity modulated radiation therapy with concurrent chemotherapy for pelvic malignancies.
Liang Y; Bydder M; Yashar CM; Rose BS; Cornell M; Hoh CK; Lawson JD; Einck J; Saenz C; Fanta P; Mundt AJ; Bydder GM; Mell LK
Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):406-14. PubMed ID: 22687195
[TBL] [Abstract][Full Text] [Related]
8. Impact of chemotherapy on normal tissue complication probability models of acute hematologic toxicity in patients receiving pelvic intensity modulated radiation therapy.
Bazan JG; Luxton G; Kozak MM; Anderson EM; Hancock SL; Kapp DS; Kidd EA; Koong AC; Chang DT
Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):983-91. PubMed ID: 24161422
[TBL] [Abstract][Full Text] [Related]
9. Pelvic bone marrow sparing intensity modulated radiotherapy reduces the incidence of the hematologic toxicity of patients with cervical cancer receiving concurrent chemoradiotherapy: a single-center prospective randomized controlled trial.
Huang J; Gu F; Ji T; Zhao J; Li G
Radiat Oncol; 2020 Jul; 15(1):180. PubMed ID: 32727497
[TBL] [Abstract][Full Text] [Related]
10. Hematologic toxicity in RTOG 0418: a phase 2 study of postoperative IMRT for gynecologic cancer.
Klopp AH; Moughan J; Portelance L; Miller BE; Salehpour MR; Hildebrandt E; Nuanjing J; D'Souza D; Souhami L; Small W; Gaur R; Jhingran A
Int J Radiat Oncol Biol Phys; 2013 May; 86(1):83-90. PubMed ID: 23582248
[TBL] [Abstract][Full Text] [Related]
11. A prospective single-arm study on the relationship between dose-volume parameters of pelvic functional bone marrow and acute hematological toxicities during intensity-modulated radiotherapy with or without concurrent chemotherapy for uterine cervical/endometrial cancer.
Chen H; Zhong Q; Liu Y; Li J; Deng W; Wang J; Zhou S; Yu Z; Huang X; Huang Y; Zhen B; Wei J; Zhang W; Ruan X; Xiao L
Radiat Oncol; 2023 Nov; 18(1):193. PubMed ID: 38012675
[TBL] [Abstract][Full Text] [Related]
12. Comparison of hematologic toxicity between 3DCRT and IMRT planning in cervical cancer patients after concurrent chemoradiotherapy: a national multi-center study.
Erpolat OP; Alco G; Caglar HB; Igdem S; Saran A; Dagoglu N; Aslay I; Ozsaran Z; Demirci S; Keven E; Guney Y; Akmansu M; Kilic D; Bayman E; Etiz D; Mandel NM
Eur J Gynaecol Oncol; 2014; 35(1):62-6. PubMed ID: 24654465
[TBL] [Abstract][Full Text] [Related]
13. Dosimetric predictors of acute hematologic toxicity during concurrent intensity-modulated radiotherapy and chemotherapy for anal cancer.
Franco P; Ragona R; Arcadipane F; Mistrangelo M; Cassoni P; Rondi N; Morino M; Racca P; Ricardi U
Clin Transl Oncol; 2017 Jan; 19(1):67-75. PubMed ID: 27037814
[TBL] [Abstract][Full Text] [Related]
14. Normal tissue complication probability analysis of acute gastrointestinal toxicity in cervical cancer patients undergoing intensity modulated radiation therapy and concurrent cisplatin.
Simpson DR; Song WY; Moiseenko V; Rose BS; Yashar CM; Mundt AJ; Mell LK
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):e81-6. PubMed ID: 22516388
[TBL] [Abstract][Full Text] [Related]
15. Intensity-Modulated Radiotherapy (IMRT) vs Helical Tomotherapy (HT) in Concurrent Chemoradiotherapy (CRT) for Patients with Anal Canal Carcinoma (ACC): an analysis of dose distribution and toxicities.
Yeung R; McConnell Y; Warkentin H; Graham D; Warkentin B; Joseph K; Doll CM
Radiat Oncol; 2015 Apr; 10():92. PubMed ID: 25903798
[TBL] [Abstract][Full Text] [Related]
16. Dose-volume effects for pelvic bone marrow in predicting hematological toxicity in prostate cancer radiotherapy with pelvic node irradiation.
Sini C; Fiorino C; Perna L; Noris Chiorda B; Deantoni CL; Bianchi M; Sacco V; Briganti A; Montorsi F; Calandrino R; Di Muzio N; Cozzarini C
Radiother Oncol; 2016 Jan; 118(1):79-84. PubMed ID: 26702990
[TBL] [Abstract][Full Text] [Related]
17. Radiation-related predictors of hematologic toxicity after concurrent chemoradiation for cervical cancer and implications for bone marrow-sparing pelvic IMRT.
Albuquerque K; Giangreco D; Morrison C; Siddiqui M; Sinacore J; Potkul R; Roeske J
Int J Radiat Oncol Biol Phys; 2011 Mar; 79(4):1043-7. PubMed ID: 20471182
[TBL] [Abstract][Full Text] [Related]
18. The volume of
Wang SB; Liu JP; Lei KJ; Jia YM; Xu Y; Rong JF; Wang CX
Cancer Med; 2019 Dec; 8(17):7219-7226. PubMed ID: 31621208
[TBL] [Abstract][Full Text] [Related]
19. [(18)F]FDG-PET standard uptake value as a metabolic predictor of bone marrow response to radiation: impact on acute and late hematological toxicity in cervical cancer patients treated with chemoradiation therapy.
Elicin O; Callaway S; Prior JO; Bourhis J; Ozsahin M; Herrera FG
Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1099-107. PubMed ID: 25442041
[TBL] [Abstract][Full Text] [Related]
20. Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy.
Mell LK; Schomas DA; Salama JK; Devisetty K; Aydogan B; Miller RC; Jani AB; Kindler HL; Mundt AJ; Roeske JC; Chmura SJ
Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1431-7. PubMed ID: 17996390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
